Year archive

Lytix Biopharma AS — 2023 filings

All 50 regulatory filings released by Lytix Biopharma AS (LYTIX) in 2023, sourced directly from the official regulator.

50 Filings

2023 Period

2023 filings (50)

Filing	Released	Lang
Financial calendar Report Publication Announcement	2023-12-29	English
Encouraging results from ATLAS-IT-04 study published in OncoImmunology Regulatory Filings	2023-12-11	English
Lytix Biopharma presents third quarter 2023 results Earnings Release Q3 2023	2023-11-09	English
Lytix Biopharma presents third quarter 2023 results Investor Presentation	2023-11-09	English
Lytix Biopharma presents third quarter 2023 results Earnings Release Q3 2023	2023-11-09	English
Lytix Biopharma presenting at major investor conferences in London and Stockholm in November Investor Presentation	2023-11-08	English
Lytix Biopharma: Presentation of third quarter 2023 results, November 9 Report Publication Announcement	2023-11-02	English
Financial calendar Report Publication Announcement	2023-10-25	English
Encouraging preliminary data from Lytix Biopharma’s ATLAS-IT-05 study presented at ESMO 2023 Regulatory Filings	2023-10-23	English
Lytix Biopharma to host webcast after release of preliminary data from ATLAS-IT-05 Report Publication Announcement	2023-10-20	English
Lytix Biopharma granted up to NOK14.3m (US$1.3m) of public non-dilutive funding from ’SkatteFUNN’ Regulatory Filings	2023-10-17	English
Lytix Biopharma’s abstract with preliminary interim Phase II data from the ATLAS-IT-05 study is published Regulatory Filings	2023-10-16	English
Neoadjuvant study with LTX-315 in early-stage melanoma patients to be presented at the 15th Nordic melanoma meeting Regulatory Filings	2023-10-09	English
Neoadjuvant study with LTX-315 in early-stage melanoma patients to be presented at the 15th Nordic melanoma meeting Regulatory Filings	2023-10-09	English
Lytix Biopharma presents first half and second quarter 2023 results Earnings Release H1 2023	2023-08-31	English
Lytix Biopharma presents first half and second quarter 2023 results Investor Presentation	2023-08-31	English
Lytix Biopharma presents first half and second quarter 2023 results Interim / Quarterly Report H1 2023	2023-08-31	English
Lytix Biopharma presents first half and second quarter 2023 results Earnings Release H1 2023	2023-08-31	English
Lytix Biopharma announces completion of patient recruitment in the ATLAS-IT-05 trial Regulatory Filings	2023-08-28	English
Lytix Biopharma: Presentation of second quarter 2023 results, August 31 Report Publication Announcement	2023-08-24	English
Lytix Biopharma’s licensing partner Verrica Pharmaceuticals Inc. reports interim Phase II data with LTX-315 Regulatory Filings	2023-08-11	English
Lytix Biopharma’s licensing partner Verrica Pharmaceuticals Inc. reports interim Phase II data with LTX-315 Earnings Release Q3 2023	2023-08-11	English
Lytix Biopharma announces presentation of interim data from ATLAS-IT-05 study at ESMO 2023 Regulatory Filings	2023-07-20	English
Lytix Biopharma AS: GRANT OF SHARE OPTIONS Remuneration Information	2023-06-21	English
Lytix Biopharma to present at ABG Sundal Collier Life Science Summit and Redeye Growth Day in Stockholm Regulatory Filings	2023-05-25	English
Lytix Biopharma presents first quarter 2023 results Earnings Release Q1 2023	2023-05-11	English
Lytix Biopharma presents first quarter 2023 results Investor Presentation	2023-05-11	English
Lytix Biopharma presents first quarter 2023 results Earnings Release Q1 2023	2023-05-11	English
Lytix Biopharma: Presentation of first quarter 2023 results, Thursday 11 May Report Publication Announcement	2023-05-04	English
Lytix Biopharma to present at the ‘Frontiers in Cancer Immunotherapy 2023’, invited by New York Academy of Sciences Regulatory Filings	2023-05-03	English
Lytix Biopharma appoints new Chairman of the Board Board/Management Information	2023-04-19	English
Lytix Biopharma AS: GRANT OF SHARE OPTIONS Share Issue/Capital Change	2023-04-18	English
Lytix Biopharma AS: GRANT OF SHARE OPTIONS Delisting Announcement	2023-04-18	English
Lytix Biopharma AS: GRANT OF SHARE OPTIONS Delisting Announcement	2023-04-18	English
Lytix Biopharma AS: GRANT OF SHARE OPTIONS Regulatory Filings	2023-04-18	English
Lytix Biopharma AS: GRANT OF SHARE OPTIONS Delisting Announcement	2023-04-18	English
Lytix Biopharma AS: GRANT OF SHARE OPTIONS Delisting Announcement	2023-04-18	English
Lytix Biopharma AS: GRANT OF SHARE OPTIONS Share Issue/Capital Change	2023-04-18	English
Lytix Biopharma – Minutes of Ordinary General Meeting AGM Information	2023-04-18	English
Lytix Biopharma – Minutes of Ordinary General Meeting AGM Information	2023-04-18	English
Lytix Biopharma AS: Notice of Annual General Meeting on 18 April 2023 AGM Information	2023-04-11	English
Lytix Biopharma AS: Notice of Annual General Meeting on 18 April 2023 Annual Report FY 2022	2023-04-11	English
Lytix Biopharma AS: Notice of Annual General Meeting on 18 April 2023 AGM Information	2023-04-11	English
Lytix Biopharma: Annual Report for 2022 Annual Report FY 2022	2023-03-30	English
Lytix Biopharma: Annual Report for 2022 Report Publication Announcement FY 2022	2023-03-30	English
Lytix Biopharma presents fourth quarter and second half 2022 results Interim / Quarterly Report FY 2022	2023-02-16	English
Lytix Biopharma presents fourth quarter and second half 2022 results Investor Presentation	2023-02-16	English
Lytix Biopharma presents fourth quarter and second half 2022 results Interim / Quarterly Report Q4 2022	2023-02-16	English
Lytix Biopharma presents fourth quarter and second half 2022 results Earnings Release H2 2022	2023-02-16	English
Lytix Biopharma: Invitation to presentation of fourth quarter and second half 2022 results, Thursday 16 February Earnings Release Q4 2022	2023-02-09	English